Valeant Parkinson’s Treatment Zelapar “Approvable” For Second Time
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s latest letter on the orally disintegrating selegiline product “requests additional clarification on specific issues previously addressed by Valeant,” the company says.